RVTY REVVITY, INC.
Laboratory Analytical Instruments · NYSE · SEC CIK 31791 · Fiscal year ends 12/29
Financial factors as of 2026-10-04 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.6%
TTM net income YoY6.6%
TTM EPS YoY12.6%
Revenue 3-yr CAGR1.7%
Net income 3-yr CAGR-30.1%
Margins
Gross margin—
Operating margin12.6%
Net margin8.6%
FCF margin20.1%
EBITDA margin20.9%
Returns
ROE3.5%
ROA2.1%
ROIC (approx.)3.5%
Asset turnover0.25x
Leverage & solvency
Liabilities / assets36.7%
Debt / equity0.36x
Current ratio2.65x
Interest coverage4.04x
Cash quality & payout
Operating cash flow / net income2.59x
Accruals ratio-3.4%
Payout ratio12.4%
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-28 | FY20242024-12-29 |
|---|---|---|
| Income statement | ||
| Revenue | $2.86B | $2.76B |
| R&D expense | $215.84M | $196.84M |
| SG&A expense | $991.89M | $994.07M |
| Operating income | $356.63M | $346.74M |
| Interest expense | $92.19M | $96.28M |
| Pretax income | $268.28M | $316.13M |
| Income tax | $28.39M | $33.05M |
| Net income | $241.20M | $270.38M |
| EBITDA | $761.98M | $774.59M |
| EPS (basic) | 2.07 | 2.21 |
| EPS (diluted) | 2.07 | 2.20 |
| Dividends declared per share | 0.28 | 0.28 |
| Weighted avg. shares (diluted) | 116.59M | 122.82M |
| Balance sheet | ||
| Cash & equivalents | $919.86M | $1.16B |
| Short-term investments | — | $0 |
| Receivables | $744.67M | $632.40M |
| Inventory | $379.50M | $367.59M |
| Current assets | $2.24B | $2.35B |
| PP&E, net | $479.25M | $482.22M |
| Goodwill | $6.61B | $6.46B |
| Intangibles | $2.35B | $2.64B |
| Total assets | $12.17B | $12.39B |
| Current liabilities | $1.33B | $653.10M |
| Short-term debt | $588.83M | $242,000 |
| Long-term debt | $2.63B | $3.15B |
| Total debt | $3.22B | $3.15B |
| Total liabilities | $4.92B | $4.73B |
| Shareholders' equity | $7.25B | $7.67B |
| Net debt | $2.30B | $1.99B |
| Shares outstanding | 112.28M | 120.65M |
| Cash flow statement | ||
| Operating cash flow | $582.93M | $628.30M |
| Capital expenditure | $73.52M | $86.65M |
| Free cash flow | $509.41M | $541.65M |
| Investing cash flow | -$17.35M | $776.16M |
| Financing cash flow | -$857.52M | -$1.13B |
| Depreciation & amortization | $405.34M | $427.85M |
| Stock-based compensation | $22.85M | $37.81M |
| Dividends paid | $32.80M | $34.45M |
| Share buybacks | $820.82M | $369.58M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.